8-K: Teknova Reports Modest Revenue Growth in Q1 2024, Reaffirms Full-Year Guidance

Alpha Teknova reported a 2% increase in revenue for the first quarter of 2024, reaching $9.3 million, and reaffirmed its full-year revenue guidance of $35-38 million.

Summary

• Alpha Teknova's total revenue for the first quarter of 2024 was $9.3 million, a 2% increase compared to $9.1 million in the same period last year.
• Lab Essentials revenue remained flat at $7.3 million, while Clinical Solutions revenue grew by 7% to $1.7 million.
• The company's gross profit decreased to $2.2 million from $2.4 million year-over-year, with a gross margin of 23.8% compared to 26.6% in the first quarter of 2023.
• Operating expenses decreased to $10.2 million from $11.4 million, primarily due to reduced headcount and spending.
• Net loss improved to $8.1 million, or negative $0.20 per diluted share, compared to a net loss of $8.8 million, or negative $0.31 per diluted share, in the first quarter of 2023.
• Adjusted EBITDA was negative $3.8 million, an improvement from negative $6.1 million in the prior year's first quarter.
• Free cash flow was negative $6.7 million, compared to negative $12.0 million in the first quarter of 2023.
• Teknova reaffirmed its 2024 revenue guidance of $35-38 million and free cash outflow of less than $18 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenue growth was modest and gross margins declined, the company showed improvements in operating expenses, net loss, adjusted EBITDA, and free cash flow. The reaffirmation of full-year guidance also provides some confidence.

Positives

• The company saw a 7% increase in Clinical Solutions revenue.
• Operating expenses decreased due to reduced headcount and spending.
• Net loss per share improved from negative $0.31 to negative $0.20.
• Adjusted EBITDA and free cash flow showed significant improvements year-over-year.
• Teknova launched innovative products like Build-Tek Solutions and AAV-Tek AAV Stabilizer.

Negatives

• Gross profit decreased to $2.2 million from $2.4 million year-over-year.
• Gross margin declined to 23.8% from 26.6% due to increased overhead costs.
• Lab Essentials revenue remained flat year-over-year.
• The company reported a net loss of $8.1 million for the quarter.

Risks

• The company's performance is subject to demand for its products and potential delays or pauses in customer orders.
• Teknova relies on a limited number of customers for a significant portion of its revenue.
• Global economic and marketplace uncertainties, including conflicts in Ukraine and the Middle East, could impact the company.
• The company's supply chain, sourcing, manufacturing, and warehousing are subject to risks.
• There are risks associated with potential acquisitions and integration of other companies.

Future Outlook

Teknova reaffirms its 2024 revenue guidance of $35-38 million, with approximately 10% growth expected in Lab Essentials and the remainder from Clinical Solutions, and anticipates free cash outflow of less than $18 million for 2024.

Management Comments

• Stephen Gunstream, President and CEO, stated he was pleased with the company's performance in the first quarter and highlighted the launch of Build-Tek Solutions.
• Matt Lowell, CFO, noted the company managed operating expenses and capital expenditures to plan, reinforcing belief in the full-year outlook.

Industry Context

Teknova operates in the life sciences industry, providing critical reagents for the development of therapies, vaccines, and diagnostics. The launch of Build-Tek Solutions and AAV-Tek AAV Stabilizer indicates a focus on innovation and addressing customer needs in early-stage research and development. The company's performance is influenced by trends in the biotech and pharmaceutical sectors, including demand for novel therapies and diagnostics.

Comparison to Industry Standards

• Teknova's 2% revenue growth is modest compared to some high-growth biotech companies, but it is in line with companies focused on supplying research and development reagents.
• The decrease in gross margin is a concern, as many companies in the sector aim for higher margins through efficient manufacturing and pricing strategies.
• The improvement in adjusted EBITDA and free cash flow is a positive sign, as these metrics are closely watched by investors in the biotech industry.
• Companies like Thermo Fisher Scientific and Danaher, which are larger players in the life sciences tools and reagents market, often report higher revenue growth and profitability, but they also have a broader product portfolio and customer base.
• Teknova's focus on custom solutions and fast turnaround times differentiates it from some of the larger players, but it also faces competition from smaller, specialized reagent providers.

Stakeholder Impact

• Shareholders may view the modest revenue growth and decreased gross margin with some concern, but the improvements in other financial metrics and reaffirmed guidance are positive.
• Employees may be impacted by the reduced headcount, but the company's focus on innovation and growth could provide future opportunities.
• Customers will benefit from the new product offerings, such as Build-Tek Solutions and AAV-Tek AAV Stabilizer.
• Suppliers may see continued demand for their products as Teknova continues to operate and grow.

Next Steps

• Teknova will attend the William Blair 44th Annual Growth Stock Conference from June 4-6, 2024.
• The company will host a webcast and conference call on May 13, 2024, to discuss the results.

Key Dates

Keywords

reagents, biotech, life sciences, financial results, revenue, EBITDA, cash flow, clinical solutions, lab essentials, AAV, buffer, manufacturing